A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Latest Information Update: 15 May 2024
At a glance
- Drugs TAK 007 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 10 May 2024 Status changed from recruiting to active, no longer recruiting.
- 29 Feb 2024 Planned number of patients changed from 242 to 265.
- 29 Feb 2024 Planned End Date changed from 26 Oct 2029 to 20 Jun 2030.